ID   MCF10A_TET2_B3
AC   CVCL_C1AH
DR   EGA; EGAD00001008559
DR   Wikidata; Q114312265
RX   PubMed=35692635;
CC   Part of: Cancer Pathway Knockout Panel.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008359.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0598 ! MCF-10A
SX   Female
AG   36Y
CA   Spontaneously immortalized cell line
DT   Created: 22-09-22; Last updated: 29-06-23; Version: 4
//
RX   PubMed=35692635; DOI=10.1016/j.isci.2022.104437;
RA   Cook A.L., Wyhs N., Sur S., Ptak B., Popoli M., Dobbyn L.,
RA   Papadopoulos T., Bettegowda C., Papadopoulos N., Vogelstein B.,
RA   Zhou S.-B., Kinzler K.W.;
RT   "An isogenic cell line panel for sequence-based screening of targeted
RT   anticancer drugs.";
RL   IScience 25:104437.1-104437.14(2022).
//